This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...

The Phase II study found that lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor.

Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

An experimental drug could be game-changing for millions of Americans with a higher genetic risk of cardiovascular disease.

Researchers examined a real-world low-carbohydrate high-fat (LCHF) diet population to assess links between nutrient intake and cardiovascular risk.

A single dose of an experimental drug dramatically reduced levels of a deadly form of cholesterol, often thought to be ...

People with low levels of low-density lipoprotein cholesterol (LDL-C) in their blood have a lower risk of dementia, including ...

Lilly's drug is one of several being tested to treat high Lp(a), a risk factor for heart disease that affects an estimated ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) ...

Corporation highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic acid, EPA, on ...